Individualized therapy for persistent asthma in young children.

Area of Science:

• Pediatric Pulmonology
• Allergy and Immunology
• Clinical Trial Research

Background:

• Asthma presentations vary in young children, influencing treatment effectiveness.
• Step 2 asthma therapy in toddlers requires tailored approaches.
• Understanding differential medication responses is crucial for effective asthma management.

Purpose of the Study:

• To investigate differential responses to asthma controller medications in toddlers.
• To identify predictors of treatment response in pediatric asthma.
• To evaluate the efficacy of inhaled corticosteroids (ICSs) versus leukotriene receptor antagonists.

Main Methods:

• A multicenter, randomized, double-blind, double-dummy trial involving 300 children aged 12-59 months with asthma.
• Crossover design comparing daily ICS, daily leukotriene receptor antagonists, and as-needed ICS with albuterol.
• Primary outcome: composite measure of asthma control; secondary analysis: prediction of differential response by sensitization, exacerbations, and sex.

Main Results:

• 74% of children showed differential responses to the three treatment strategies.
• Daily ICS provided the best response probability, particularly in those with aeroallergen sensitization.
• Aeroallergen sensitization and blood eosinophil counts ≥300/μL identified children benefiting most from daily ICS.

Conclusions:

• Phenotyping young children with asthma using aeroallergen sensitization and eosinophil counts guides treatment selection.
• Daily ICS is beneficial for children with high exacerbation probability and specific biomarkers.
• This approach optimizes asthma control in toddlers, balancing efficacy and potential risks.